Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an oral P2Y$_{12}$ platelet inhibitor used to prevent thrombotic events. It is a direct-acting, reversible antagonist.
## Primary Indications
* Reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
* Prevention of thrombotic cardiovascular events in patients with ACS undergoing percutaneous coronary intervention (PCI).
## Adult Dosing
* **ACS:** 180 mg orally once, then 90 mg orally twice daily for up to 12 months.
* **ACS with PCI:** 180 mg orally once, then 90 mg orally twice daily. Duration is typically 12 months, but may be extended based on individual risk.
* **Maintenance therapy post-MI:** 60 mg orally twice daily.
## Pediatric Dosing
There is no established pediatric dosing for ticagrelor.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is needed in patients with mild to moderate hepatic impairment. Safety and efficacy have not been studied in severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is needed in patients with mild to moderate renal impairment. In severe renal impairment, consider the risks and benefits.
## Contraindications
* Active pathological bleeding.
* History of transient ischemic attack (TIA) or stroke.
* Hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Common:** Dyspnea, bleeding (including fatal and life-threatening), bradycardia, diarrhea, rash.
* **Serious:** Major bleeding, non-major clinically relevant bleeding, ventricular pauses, increased creatinine.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) may increase ticagrelor exposure.
* **CYP3A4 Inducers:** Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) may decrease ticagrelor exposure.
* **UGT Inhibitors/Inducers:** Ticagrelor is a substrate for UGT enzymes.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Periodically monitor serum creatinine and potassium levels, especially in patients with severe renal impairment.
## Clinical Pearls
* Ticagrelor should be taken for the duration recommended by the prescribing physician.
* Patients should be instructed not to stop ticagrelor without consulting their physician due to increased risk of thrombotic events.
* Aspirin should be used concurrently with ticagrelor at the lowest effective dose in patients with ACS. The maintenance dose of ticagrelor (60 mg twice daily) can be used in patients with a history of MI for longer-term therapy, irrespective of aspirin use.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant literature for complete and up-to-date guidance.
